News Sentiment

FBIO sentiment intelligence

Fortress Biotech Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 61 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.99 Week of 19 Jun 2026
Weighted tone 61/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend inactive

+7.9% over one week, +9.1% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Fortress Biotech Stock - Saturday deep dive on the business model

Market Reaction

Price moving ahead of tone

70/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 7.9% Price confirming higher
Trend fit Trend inactive 9.1% over four weeks
Fair value 11.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 24
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
GlobeNewswire 6
AD HOC NEWS 3
TradingKey 3
MarketBeat 3
Stock Traders Daily 3
Seeking Alpha 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 22
Earnings 17
Regulatory and legal 6
Guidance 2
Deals and strategy 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-49 of 49
MarketBeat Direct company coverage

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Here's What Happened

Fortress Biotech (NASDAQ:FBIO) shares have surpassed their 200-day moving average, trading as high as $3.54 and closing at $3.45 on Wednesday. The company holds a "Moderate Buy" consensus rating from analysts with a target price of $16.50. Wall Street Zen and Zacks recently upgra

Tone
Positive 67/100
Event
Analyst action
Published
19 Feb 2026 09:27
Source
MarketBeat
Stock Traders Daily Direct company coverage

Behavioral Patterns of FBIOP and Institutional Flows

This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents three AI-generated trading strategies—Position, Momentum Breakout

Tone
Neutral 50/100
Event
Guidance
Published
13 Feb 2026 14:28
Source
Stock Traders Daily
MarketBeat Direct company coverage

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - What's Next?

Fortress Biotech (NASDAQ:FBIO) shares have risen above their 200-day moving average, reaching $3.74 on high volume, which is considered a bullish technical signal. The company's fundamentals are mixed, with a market capitalization of $116 million and a negative P/E, but it recent

Tone
Positive 70/100
Event
Market update
Published
11 Feb 2026 07:58
Source
MarketBeat
Aktiencheck Direct company coverage

Fortress Biotech Achieves Landmark FDA Approval for Rare Pediatric Disease Treatment ()

Fortress Biotech and its subsidiary Cyprium Therapeutics received FDA approval for ZYCUBO, the first and only approved treatment for Menkes disease in pediatric patients. This approval, based on compelling clinical data showing significant survival benefits, triggers a Rare Pedia

Tone
Positive 91/100
Event
Regulatory and legal
Published
10 Feb 2026 00:59
Source
Aktiencheck
富途牛牛 Direct company coverage

Fortress Biotech, Inc. (NASDAQ:FBIO) Might Not Be As Mispriced As It Looks After Plunging 28%

Fortress Biotech (NASDAQ:FBIO) shares have dropped 28% in the last month, though they are still up 65% over the past year. Despite a low price-to-sales (P/S) ratio of 1.5x compared to an industry average of 11.5x, its declining revenue and market skepticism about future growth fo

Tone
Neutral 50/100
Event
Earnings
Published
06 Feb 2026 03:28
Source
富途牛牛
Simply Wall Street Direct company coverage

Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower

Fortress Biotech's shares have fallen 28% in the last month, though they are still up 65% over the year. The company's price-to-sales (P/S) ratio of 1.5x is considerably lower than the industry average, largely due to a 24% decline in revenue last year. Despite analyst forecasts

Tone
Negative 32/100
Event
Earnings
Published
06 Feb 2026 02:29
Source
Simply Wall Street
Stock Traders Daily Direct company coverage

(FBIOP) Movement Within Algorithmic Entry Frameworks

This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) using AI models, identifying weak near-term sentiment but strong mid and long-term support signals. It provides three distinct AI-generated trading strategies: a Po

Tone
Neutral 50/100
Event
Market update
Published
02 Feb 2026 18:20
Source
Stock Traders Daily
Markets Mojo Direct company coverage

Fortress Biotech Leads High-Performing Stocks with 93.1% Return

Fortress Biotech, Inc. has demonstrated strong performance over the past year, leading with a 93.1% return in the Pharmaceuticals & Biotechnology sector. Other high-performing stocks include GigaCloud Technology, Inc. with a 91.39% return in Trading & Distributors, and The Toro C

Tone
Positive 92/100
Event
Market update
Published
30 Jan 2026 15:31
Source
Markets Mojo
Stock Traders Daily Direct company coverage

How (FBIOP) Movements Inform Risk Allocation Models

This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) using AI models to provide trading strategies. It highlights a near-term neutral sentiment but mid and long-term strength, along with identifying support and resist

Tone
Neutral 50/100
Event
Market update
Published
22 Jan 2026 12:12
Source
Stock Traders Daily
Market source Direct company coverage

Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability

Fortress Biotech, Inc. (NASDAQ:FBIO), a biopharmaceutical company, is projected by analysts to achieve profitability within 12 months, moving from a significant loss in previous years to an anticipated profit of US$1.3 million in 2026. This turnaround requires an aggressive avera

Tone
Positive 66/100
Event
Earnings
Published
18 Jan 2026 12:27
Source
Market source
MarketBeat Direct company coverage

Zacks Research Upgrades Fortress Biotech (NASDAQ:FBIO) to Strong-Buy

Zacks Research has upgraded Fortress Biotech (NASDAQ:FBIO) from "hold" to "Strong-Buy," while MarketBeat maintains a "Moderate Buy" consensus with a target price of $16.50. Shares increased by 6.1%, opening at $3.48, and the biopharmaceutical company recently beat EPS estimates (

Tone
Positive 72/100
Event
Earnings
Published
16 Jan 2026 13:27
Source
MarketBeat
www.marketscreener.com Direct company coverage

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO, the First and Only Approved Treatment for Menkes Disease in the United States

Fortress Biotech and its subsidiary Cyprium Therapeutics announced that the U.S. FDA has approved ZYCUBO (copper histidinate) for treating Menkes disease in pediatric patients, marking the first and only approved treatment for this rare and often fatal condition. The approval inc

Tone
Positive 92/100
Event
Regulatory and legal
Published
14 Jan 2026 12:27
Source
www.marketscreener.com
WHTC Direct company coverage

US FDA approves Fortress Bio and Zydus’ treatment for a rare pediatric disease

The U.S. FDA has approved Zycubo, a drug developed by Fortress Biotech and Zydus Lifesciences, for the treatment of Menkes disease. This marks the first approved treatment for the rare pediatric genetic disorder in the United States, which affects copper absorption and can be fat

Tone
Positive 71/100
Event
Market update
Published
14 Jan 2026 11:59
Source
WHTC